UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) (State or ot ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Cure blood cancers through cell and genome engineering | | | | | | May 2023 | | | | | | Confidential | | | | | Disclaimer This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81 ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Cure blood cancers through cell and genome engineering | | | | | | March 2023 | | | | | | Confidential | | | | | Disclaimer This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Cure blood cancers through cell and genome engineering | | | | | | February 2023 | | | | | | Confidential | | | | | Disclaimer This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company") ...

Vor Bio's Platform and Pipeline - Vor Bio is developing engineered hematopoietic stem cell transplant (eHSC) platform to unlock the potential of targeted therapies with curative intent for hematologic malignancies[73] - The company's lead program, Trem-cel, is a CD33-deleted eHSC designed to protect healthy donor cells from CD33-targeted therapies like Mylotarg and VCAR33[16, 17] - Vor Bio anticipates an IND filing for VCAR33ALLO, an allogeneic CD33-directed CAR-T therapy, in the first half of 2023[15, 45] - The company is exploring additional surface targets such as CD123, EMR2, and CD5, including multiplex genome engineering approaches[15] Trem-cel Clinical Data and Mylotarg - Initial clinical data for Trem-cel + Mylotarg in AML patients showed robust neutrophil engraftment and platelet recovery[28, 29, 30] - In the first patient treated with Trem-cel, CD33 negative cells reached 95% in peripheral blood and 92% in bone marrow by day 28 post-transplant[35] - The first patient achieved complete donor chimerism (100%) in whole blood, myeloid, and NK lineages by day 28[35] - Mylotarg, administered at 0.5 mg/m2 post-HCT, did not show evidence of myelosuppression in the first patient[43] Financials - A recent financing round raised $116 million for the company[73]

| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Cure blood cancers through cell and genome engineering | | | | | | November 2022 | | | | | | Confidential | | | | | Disclaimer This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company") ...

(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from __________________ to __________________ Commission File Number: 001-39979 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 100 Cambridgepark Drive, Suite 101 Cambridge, Massachusetts 02140 (Address of princip ...

| --- | --- | |---------------------------------------------|-------| | | | | | | | Cure blood cancers through cell and genome | | | engineering | | | September 2022 | | 1 Confidential Disclaimer This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The words "aim," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potenti ...